Lipid nanoparticles produce chimeric antigen receptor macrophages (CAR-M) in situ for the treatment of solid tumors

IF 13.2 1区 材料科学 Q1 CHEMISTRY, MULTIDISCIPLINARY
Jing-e Zhou , Ziyu Zhou , Zhehao Wang , Lei Sun , Fubing Li , Yu Tang , Rui Liu , JiaHui Liu , Xiaobin Zheng , Lei Yu , Nan Xu , Jing Wang , Zhang Zhang , Qiang Xu , Taiwei Sun , Ceshi Chen , Zhiqiang Yan
{"title":"Lipid nanoparticles produce chimeric antigen receptor macrophages (CAR-M) in situ for the treatment of solid tumors","authors":"Jing-e Zhou ,&nbsp;Ziyu Zhou ,&nbsp;Zhehao Wang ,&nbsp;Lei Sun ,&nbsp;Fubing Li ,&nbsp;Yu Tang ,&nbsp;Rui Liu ,&nbsp;JiaHui Liu ,&nbsp;Xiaobin Zheng ,&nbsp;Lei Yu ,&nbsp;Nan Xu ,&nbsp;Jing Wang ,&nbsp;Zhang Zhang ,&nbsp;Qiang Xu ,&nbsp;Taiwei Sun ,&nbsp;Ceshi Chen ,&nbsp;Zhiqiang Yan","doi":"10.1016/j.nantod.2024.102610","DOIUrl":null,"url":null,"abstract":"<div><div>Chimeric antigen receptor-macrophage (CAR-M) therapy has shown significant promise for solid tumor treatment. However, its clinical implementation faces challenges due to the intricate ex vivo manufacture procedures involved. Given that the nano drug delivery system (NDDS) is readily taken up by macrophages in vivo, we here propose a convenient approach for in situ CAR-M generation. We first developed lipid nanoparticles loaded with Trop2-CAR plasmid DNA (LNP/CAR Trop2). In vivo experiments showed that LNP/CAR Trop2 could transfect macrophages and produce CAR-M following either intravenous or intratumoral injection. Notably, the majority of CAR-M displayed an M1 phenotype, resulting in the selective elimination of Trop2-overexpressing tumor cells and a reduction in tumor volume in tumor-bearing mice. Furthermore, the produced CAR-M in situ promoted the proliferation of NK cells and CD8 + T cells, further augmenting their anti-tumor effect. This strategy transforms the inherent disadvantage of NDDSs being easily taken up by macrophages into an advantage, enabling the generation of CAR-M in situ and circumventing the complex preparation process ex vivo. This study will improve the convenience and practicality of clinical use of CAR-M and provide a new approach for solid tumors therapy.</div></div>","PeriodicalId":395,"journal":{"name":"Nano Today","volume":"61 ","pages":"Article 102610"},"PeriodicalIF":13.2000,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nano Today","FirstCategoryId":"88","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1748013224004663","RegionNum":1,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 0

Abstract

Chimeric antigen receptor-macrophage (CAR-M) therapy has shown significant promise for solid tumor treatment. However, its clinical implementation faces challenges due to the intricate ex vivo manufacture procedures involved. Given that the nano drug delivery system (NDDS) is readily taken up by macrophages in vivo, we here propose a convenient approach for in situ CAR-M generation. We first developed lipid nanoparticles loaded with Trop2-CAR plasmid DNA (LNP/CAR Trop2). In vivo experiments showed that LNP/CAR Trop2 could transfect macrophages and produce CAR-M following either intravenous or intratumoral injection. Notably, the majority of CAR-M displayed an M1 phenotype, resulting in the selective elimination of Trop2-overexpressing tumor cells and a reduction in tumor volume in tumor-bearing mice. Furthermore, the produced CAR-M in situ promoted the proliferation of NK cells and CD8 + T cells, further augmenting their anti-tumor effect. This strategy transforms the inherent disadvantage of NDDSs being easily taken up by macrophages into an advantage, enabling the generation of CAR-M in situ and circumventing the complex preparation process ex vivo. This study will improve the convenience and practicality of clinical use of CAR-M and provide a new approach for solid tumors therapy.
求助全文
约1分钟内获得全文 求助全文
来源期刊
Nano Today
Nano Today 工程技术-材料科学:综合
CiteScore
21.50
自引率
3.40%
发文量
305
审稿时长
40 days
期刊介绍: Nano Today is a journal dedicated to publishing influential and innovative work in the field of nanoscience and technology. It covers a wide range of subject areas including biomaterials, materials chemistry, materials science, chemistry, bioengineering, biochemistry, genetics and molecular biology, engineering, and nanotechnology. The journal considers articles that inform readers about the latest research, breakthroughs, and topical issues in these fields. It provides comprehensive coverage through a mixture of peer-reviewed articles, research news, and information on key developments. Nano Today is abstracted and indexed in Science Citation Index, Ei Compendex, Embase, Scopus, and INSPEC.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信